{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007051","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.719237+00:00","generated_at":"2026-06-02T16:37:30.973474+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MaxCyte Q1 revenue $11.3M (+32% YoY); updates 2024 SPL guidance to ~$5M","bullets":["Total revenue $11.3M, up 32% YoY; core revenue $8.2M, up 5%.","SPL program-related revenue $3.2M, up 292% YoY; four new SPLs signed YTD including Be Biopharma.","Net loss $9.5M vs $10.9M in Q1 2023; EBITDA loss $11.2M.","2024 guidance: core revenue flat to 5% growth; SPL revenue expected ~$5M (increase).","Cash and investments $202.5M at March 31; expects year-end cash at least $175M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007051","json":"https://secwatch.observer/filing/0001558370-24-007051.json","markdown":"https://secwatch.observer/filing/0001558370-24-007051.md","text":"https://secwatch.observer/filing/0001558370-24-007051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024007051/0001558370-24-007051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024007051/mxct-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:37:30.973474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"deb356c2065e44355e03d2069a8a7dc0a2ad75b5","claim":"MAXCYTE, INC. reported the quarter ended March 31, 2024 results: revenue $11.3 million, net income $9.5 million. Guidance raised.","evidence_excerpt":"applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. ​ First Quarter Highlights ​ · Total revenue of $11.3 million in the first quarter of 2024, an increase of 32% over the first quarter of 2023. · Core business revenue of $8.2 million in the first quarter of 2024, an increase of 5% over the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837024007051/0001558370-24-007051-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$11.3 million"},{"label":"Net income","value":"$9.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}